English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We aimed to estimate the incremental lifetime effects, costs, and net-monetary-benefit (NMB) of knowing  BRCA  information by testing of patients with low-risk localized prostate cancer (PCa) in the US and guiding subsequent screening and treatment, and the cumulative savings or losses of yearly cohort testing over 16 years. We compared two strategies: (1)‘with  BRCA  information’ and (2)‘without  BRCA  information.’ We also estimated the expected value of perfect information. The incremental NMB (INMB) quantified the monetized benefit per person of knowing  BRCA  status. The net-monetized-value of knowing  BRCA  information was estimated by multiplying the INMB with the eligible population. The INMBs of knowing  BRCA  information were $43,357 (payer) and $43,487 (society). in payer and societal perspectives, respectively. Escalated to the eligible patients in 2020, knowing  BRCA  status resulted in net monetized lifetime value of $1.7 billion (payer and society) for the 2020 cohort; and yielded accumulated net-monetized-value of $28.0 billion (payer) and $28.1 billion (society) over 16 yearly cohorts of eligible PCa patients. The economic value of knowing BRCA status for all low-risk localized PCa patients in the US provides short-term and long-term evidence for  BRCA  testing to screen early and optimize treatment.

Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment